A well designed study proved that inhibition of PKCα pathway using Sorastaurin can stabilize Treg phenotype as evidenced by maintenance of high Foxp3 and CD25 expression, and lack of IL-17A and IFNγ production and has shown efficacy in clinical trials of psoriasis [42]. This evidence concerns the gene PRKCA and psoriasis.